Ribociclib 200 mg Supplier | CDK4/6 Inhibitor

At the molecular level, ribociclib works by inhibiting cyclin-dependent kinases 4 and 6 — two proteins that play a central role in controlling the transition of cells from the G1 phase to the S phase of the cell cycle. Under normal physiological conditions, CDK4 and CDK6 form complexes with cyclin D to phosphorylate the retinoblastoma protein, releasing transcription factors that drive cell division. In hormone receptor-positive breast cancer, this pathway is frequently overactivated, leading to uncontrolled cellular proliferation.

By selectively blocking CDK4 and CDK6, ribociclib disrupts the cyclin D-CDK4/6 signaling axis, preventing retinoblastoma protein phosphorylation and effectively halting cell cycle progression. The result is inhibition of tumor cell proliferation. This mechanism of action makes ribociclib a clinically relevant option when combined with endocrine-based therapies, as it targets a key resistance pathway in HR-positive, HER2-negative advanced or metastatic breast cancer.

The first approved indication is the use of ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy. This positions ribociclib as a first-line treatment option for patients who have not previously received systemic therapy for advanced or metastatic disease. The combination leverages the complementary mechanisms of CDK4/6 inhibition and estrogen suppression to delay disease progression.

The second approved indication covers the use of ribociclib in combination with fulvestrant for patients whose disease has progressed following prior endocrine therapy. This provides a clinically validated option for patients who have already received endocrine-based treatment and require a subsequent line of therapy.

Ribokis, manufactured by Everest Pharmaceuticals Ltd. (Bangladesh), is a 200 mg film-coated tablet formulation in which each tablet contains ribociclib as the active pharmaceutical ingredient. Everest Pharmaceuticals Ltd. is a recognized Bangladeshi manufacturer operating within the country’s regulated pharmaceutical sector.

Ribotix, manufactured by Beacon Pharmaceuticals Ltd. (Bangladesh), is likewise presented as a 200 mg film-coated tablet containing ribociclib as the active substance. Beacon Pharmaceuticals Ltd. is an established Bangladeshi pharmaceutical manufacturer with a portfolio spanning oncology and other therapeutic areas.

Ribociclib has received regulatory approval from two of the world’s leading medicines authorities. The United States Food and Drug Administration (FDA) granted approval in 2017, and the European Medicines Agency (EMA) similarly approved ribociclib in 2017. These approvals were based on robust clinical trial data demonstrating efficacy and an acceptable safety profile in HR-positive, HER2-negative advanced or metastatic breast cancer.

For pharmaceutical buyers and healthcare distributors operating in Saudi Arabia, the relevant regulatory authority is the Saudi Food and Drug Authority (SFDA). Import and distribution of any pharmaceutical product within the Kingdom requires compliance with SFDA registration and licensing requirements. B2B buyers are strongly advised to consult the SFDA directly — via the official portal at sfda.gov.sa — to verify the current registration status of specific ribociclib brands and to understand applicable import documentation requirements.

Common side effects include neutropenia, leukopenia, nausea, fatigue, diarrhea, vomiting, constipation, and anemia. Neutropenia is among the most frequently observed hematological findings and typically requires monitoring of complete blood counts throughout treatment.

Serious adverse reactions associated with ribociclib include QT prolongation, ventricular arrhythmia, and sudden cardiac death. Cardiac monitoring — including electrocardiogram assessment — is an important clinical consideration prior to and during therapy. Additional serious risks include hepatotoxicity, neutropenic fever, and severe infections. Liver function tests should be monitored at appropriate intervals as directed by the treating physician.

Drug interactions: Ribociclib is metabolized via the CYP3A4 pathway. Concomitant use of strong CYP3A4 inhibitors or inducers may significantly alter ribociclib plasma concentrations, and prescribers should review all concurrent medications for potential interactions before initiating therapy.

Reproductive and lactation considerations: Ribociclib is an antineoplastic agent. Females of childbearing potential must use effective contraception during treatment and for an appropriate period following the last dose. Lactation guidance should follow institutional protocols for antineoplastic agents.

Tablets should be swallowed whole and must not be crushed, split, or chewed prior to ingestion. Ribociclib tablets may be taken with or without food, offering flexibility in administration relative to mealtimes.

Ribociclib has become a globally recognized treatment in the oncology landscape for HR-positive, HER2-negative advanced breast cancer — a context in which the molecule was developed and validated through large-scale international clinical programs, including under the originator brand Kisqali. Our supply focuses exclusively on Bangladeshi-manufactured equivalents, providing a cost-accessible and reliably sourced alternative for the Saudi market.

We supply exclusively Bangladeshi-manufactured ribociclib brands — Ribokis and Ribotix — ensuring full transparency in product origin and manufacturing traceability. Our export operations are structured to meet the documentation and compliance requirements of the Saudi Arabian import process, and our team provides hands-on regulatory documentation support to streamline procurement workflows.

We serve a diverse range of institutional buyers, including hospital pharmacies, oncology centers, and pharmaceutical distributors, and we understand the operational demands of B2B healthcare supply chains. Our logistics processes are designed for consistency, with clear communication at every stage of the order and fulfillment cycle.